Article Sidebar

PDF
Date Published: 11/07/2022
Online Published: 11/07/2022
Abstract Views: 331
Views PDF: 195
DOI: https://doi.org/10.55046/vjrnm.25.643.2016
Issue
No. 25 (2016)
Section
Scientific research
How to Cite
Mai , T. K., Tran, D. H., Pham, V. T., & Dang, T. V. (2022). Evaluation the role of PET/CT in thestaging of Non-Small Cell Lung Cancer (NSCLC) at the Nuclear Medicine and Oncology Center, Bach Mai Hospital. Vietnamese Journal of Radiology and Nuclear Medicine, 25, 65-72. https://doi.org/10.55046/vjrnm.25.643.2016

Evaluation the role of PET/CT in thestaging of Non-Small Cell Lung Cancer (NSCLC) at the Nuclear Medicine and Oncology Center, Bach Mai Hospital

Dr Mai Trong Khoa1, Dr Tran Dinh Ha1, Dr Pham Van Thai1, Dr Dang Tai Voc1
1 Center for Traditional Medicine and Oncology – Bach Mai Hospital

Main Article Content

Abstract

Purposes: Evaluation the role of PET/CT in the staging of NSCLC. Methods and Materials: Retrospectiveand prospective
clinical interventions in 81 diagnosed NSCLC patients, who were taken PET/CT at the Nuclear Medicine and Oncology Center,
Bach Mai hospital from January 2014 to May 2016.
Results: The patients’average age was 59years old (from the youngest 34 to the oldest 77). The male/female rate: 37/1. The
detection ratio of lymph node metastasis and bone metastasis were changed from 48.2% to 76.5% and from 14.8% to 32.1%,
respectively. 25 patients (30.8%) were increased and 3 patients (3.7%) were reduced their staging by using PET/CT compared with other methods. The grade IV patients were raised from 51.8% to 56.8% and 32% of the patients were changed therapy plan.
Conclusion: PET/CT is anadvantaged method in the staging of NSCLC. Staging NSCLC accurately is essential for treatment
outcomes as it guided the optimal therapy for individual patient.

Article Details

Keywords

PET/CT, Non small cell lung cancer (NSCLC)

References

1. Ferlay J, Soerjomataram I, Dikshit R, et al,(2014). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN
2012.Int J Cancer J Int Cancer.
2. Ferlay J, Soerjomataram I, Ervik M, et al,(2013). Lung Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012. Available from: http:// globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
3. Mai Trọng Khoa, Trần Hải Bình (2011). Giá trị của PET/CT trong chẩn đoán ung thư phổi không tế bào nhỏ. Tạp Chí Ung Thư Học Việt Nam. Số 2:101–8.
4. Mai Trọng Khoa, Trần Đình Hà và cs (2014). Nghiên cứu hiệu quả của phác đồ Paclitaxel kết hợp Carboplatin trong điều trị ung thư phổi không tế bào nhỏ giai đoạn IV. Tạp chí ung thư học Việt Nam .Số 2:161–7.
5. Phạm Văn Thái (2015). Đánh giá kết quả điều trị ung thư phổi không tế bào nhỏ di căn não bằng hóa chất phác đồ PC kết hợp xạ phẫu dao gamma quay. Luận án Tiến sĩ Y học.
6. Nguyễn Bá Đức, Trần Văn Thuấn, Lê Thanh Đức (2008). Bệnh ung thư phổi, Nhà xuất bản Y học . Trang 134 - 152.
7. Fangfang Chen vs cs (2015). Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer. Transl Lung Cancer Res. 2015 Feb; 4(1): 18–26.
8. Trần Minh Thông, Nguyễn Xuân Cảnh, Lưu Ngọc Mai (2014). Đối chiếu giải phẫu bệnh và đặc điểm FDG PET/CT của ung thư phổi. Tạp chí Y học TPHCM. Số 2: 458- 465.
9. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. (1999). Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT.Radiology. 1999 Nov;213(2):530-6.
10. Yuehong Wang et al (2015). Evaluation of the factors affecting the maximum standardized uptake value of metastatic lymph nodes in different histological types of non-small cell lung cancer on PET-CT. BMC Pulm Med. 2015; 15: 20